SCHEMBL21803032

SCHEMBL21803032

COc1c(Nc2c(N[C@@H](c3nn(C)cc3C)C3(C)CCCC3)c(=O)c2=O)ccnc1C(=O)N1CCOCC1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CCR6 P51684 3/20 0.63
▸ CCR7 P32248 1/20 0.63
▸ CXCR2 P25025 13/20 0.41
▸ CXCR1 P25024 12/20 0.41
▸ CXCR3 P49682 1/20 0.33
▸ IRAK4 Q9NWZ3 1/20 0.32
▸ PIK3CD O00329 1/20 0.32
▸ PIK3R2 O00459 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ PIK3CB P42338 1/20 0.32
▸ PIK3CG P48736 1/20 0.32
▸ PIK3R5 Q8WYR1 1/20 0.32
▸ PIK3R3 Q92569 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.31
▸ ATM Q13315 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ SYK P43405 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21803034 1.00 CCR6 (0.63) CCR6CCR7CXCR2CXCR1CXCR3
SCHEMBL21803017 0.91 CCR6 (0.74) CCR6CCR7CXCR2CXCR1CXCR3
SCHEMBL21803018 0.91 CCR6 (0.74) CCR6CCR7CXCR2CXCR1CXCR3
SCHEMBL31688227 0.91 CCR6 (0.74) CCR6CCR7CXCR2CXCR1CXCR3
SCHEMBL21803084 0.89 CCR6 (0.69) CCR6CCR7CXCR2CXCR1CXCR3
SCHEMBL21803085 0.89 CCR6 (0.69) CCR6CCR7CXCR2CXCR1CXCR3
SCHEMBL23621408 0.86 CCR6 (0.81) CCR6CCR7CXCR2CXCR1CXCR3
SCHEMBL28550096 0.85 CCR7 (0.65) CCR6CCR7CXCR2CXCR1
SCHEMBL29113236 0.85 CCR7 (0.65) CCR6CCR7CXCR2CXCR1
SCHEMBL30536949 0.85 CCR7 (0.65) CCR6CCR7CXCR2CXCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312344-B2 N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors PFIZER INC. (US) 2025-05-27 — — US disclosed
US-20240368144-A1 N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS PFIZER INC. (US) 2024-11-07 — — US disclosed
CN-116874466-A N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors 辉瑞公司 2023-10-13 — — CN disclosed
CN-112672791-B N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors 辉瑞公司 2023-10-03 — — CN disclosed
US-11708360-B2 N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors PFIZER INC. (US) 2023-07-25 — — US disclosed
US-20210206757-A1 N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS PFIZER INC. (US) 2021-07-08 — — US disclosed
CN-112672791-A N-substituted dioxocyclobutenylamino-3-hydroxy-pyridinecarboxamides useful as CCR6 inhibitors 辉瑞公司 2021-04-16 — — CN disclosed
US-10975065-B2 N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors PFIZER INC. (US) 2021-04-13 — — US disclosed
US-20200095239-A1 N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS PFIZER INC. (US) 2020-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210206757-A1 N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS CCR6, CCR1, CCR3 CCR6 1/4885CCR7 19/4885CXCR2 13/4885
US-20240368144-A1 N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS CCR6, CCR1, CCR3 CCR6 1/4885CCR7 19/4885CXCR2 13/4885
US-11708360-B2 N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors CCR6, CCR1, CCR3 CCR6 1/4885CCR7 19/4885CXCR2 13/4885
US-20200095239-A1 N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS CCR6, CCR1, CCR3 CCR6 1/4885CCR7 19/4885CXCR2 13/4885
US-12312344-B2 N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors CCR6, CCR1, CCR3 CCR6 1/4885CCR7 19/4885CXCR2 13/4885
US-10975065-B2 N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors CCR6, CCR1, CCR3 CCR6 1/4885CCR7 19/4885CXCR2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback